



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, June 3, 2020

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), is hereby reported the following:

OTHER RELEVANT INFORMATION

We hereby inform that Pharma Mar, S.A. will host a virtual Key Opinion Leader (KOL) event on lurbinectedin and Small Cell Lung Cancer (SCLC) on Wednesday, June 10th, 2020, from 2 pm to 3 pm, EDT (8 pm to 9 pm, CET).

The event will feature a KOL discussion with Dr. Hossein Borghaei, Chief of Thoracic Medical Oncology, Professor in The Department of Hematology/Oncology at Fox Chase Cancer Center, and member of the Lung Cancer Expert Medical Advisory Panel at the American Lung Association. Dr. Borghaei will provide an overview of SCLC, current standards of care, lurbinectedin monotherapy data and potential lurbinectedin use in the clinic.

PharmaMar and its partner in the USA, Jazz Pharmaceuticals, previously announced that lurbinectedin is currently undergoing FDA evaluation, with the New Drug Application (NDA) under priority review for accelerated approval in the US for the treatment of patients with SCLC who have progressed following previous platinum therapy, with or without immunotherapy. The FDA has set a PDUFA target action date of August 16th, 2020.

A live webinar of the event will be available by using the following link: https://us02web.zoom.us/webinar/register/WN_VNUWp9BNRO2ZWb8-8FXd2A or visiting the [Events Calendar](#) of PharmaMar's website.

Please find attached press release that will be distributed to the media today.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



PharmaMar To Host Virtual KOL Event on Lurbinectedin

- The FDA has set a PDUFA target action date of August 16th, 2020

Madrid, June 3rd, 2020.- PharmaMar (MSE:PHM) has announced today that it will host a virtual Key Opinion Leader (KOL) event on lurbinectedin and Small Cell Lung Cancer (SCLC) on Wednesday, June 10th, 2020, from 2 pm to 3 pm, EDT (8 pm to 9 pm, CET).

The event will feature a KOL discussion with Dr. Hossein Borghaei, Chief of Thoracic Medical Oncology, Professor in The Department of Hematology/Oncology at Fox Chase Cancer Center, and member of the Lung Cancer Expert Medical Advisory Panel at the American Lung Association. Dr. Borghaei will provide an overview of SCLC, current standards of care, lurbinectedin monotherapy data and potential lurbinectedin use in the clinic.

PharmaMar and its partner in the USA, Jazz Pharmaceuticals, previously announced that lurbinectedin is currently undergoing FDA evaluation, with the New Drug Application (NDA) under priority review for accelerated approval in the US for the treatment of patients with SCLC who have progressed following previous platinum therapy, with or without immunotherapy. The FDA has set a PDUFA target action date of August 16th, 2020.

A live webinar of the event will be available by using the following link: https://us02web.zoom.us/webinar/register/WN_VNUWp9BNRO2ZWb8-8FXd2A or visiting the [Events Calendar](#) of PharmaMar's website.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.



PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 9184466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500



Or please visit our website at www.pharmamar.com